Table 3.
Multivariable models for the CD8 and CD20 TIL density (cells/mm2) and TNM-I (a combination of CD8 TIL density and pStage) in the overall cohort and in the LUSC and LUAD subgroups (Cox proportional hazards test, n = 553, 307 and 239, respectively)
| CD8, overall | CD8, LUSC | CD8, LUAD | CD20, overall | CD20, LUSC | CD20, LUAD | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Gender | ||||||||||||
| Female | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Male | 1.4 (1.03–1.89) | 0.028 | 1.54 (0.93–2.56) | 0.095 | 1.61 (1.08–2.41) | 0.019 | 1.49 (1.1–2.02) | 0.011 | 1.59 (0.95–2.66) | 0.079 | 1.68 (1.12–2.52) | 0.012 |
| ECOG | ||||||||||||
| 0 | 1 | 1 | 1 | 1 | ||||||||
| 1 | 1.43 (1.07–1.9) | 0.015 | 1.57 (1.02–2.41) | 0.041 | 1.45 (1.09–1.93) | 0.011 | 1.98 (1.27–3.07) | 0.002 | ||||
| 2 | 1.36 (0.73–2.54) | 0.329 | 1.01 (0.4–2.59) | 0.976 | 1.35 (0.74–2.47) | 0.322 | 1.4 (0.58–3.36) | 0.456 | ||||
| Differentiation | ||||||||||||
| Poor | 1 | 1 | 1 | |||||||||
| Moderate | 0.77 (0.58–1.04) | 0.092 | 0.65 (0.42–1.01) | 0.054 | 0.65 (0.42–1.01) | 0.055 | ||||||
| Well | 0.56 (0.35–0.92) | 0.022 | 0.56 (0.25–1.26) | 0.158 | 0.74 (0.33–1.69) | 0.475 | ||||||
| Vascular infiltration | ||||||||||||
| No | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Yes | 1.72 (1.23–2.41) | 0.002 | 1.95 (1.19–3.19) | 0.008 | 1.73 (1.06–2.82) | 0.027 | 1.82 (1.29–2.56) | <0.001 | 2 (1.19–3.37) | 0.009 | 1.65 (1.01–2.7) | 0.047 |
| pStage | ||||||||||||
| I | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| II | 1.55 (1.09–2.2) | 0.014 | 1.42 (0.84–2.39) | 0.190 | 1.93 (1.19–3.13) | 0.007 | 1.6 (1.13–2.27) | 0.009 | 1.49 (0.88–2.54) | 0.138 | 1.79 (1.1–2.92) | 0.018 |
| III | 3.36 (2.37–4.78) | <0.001 | 3.9 (2.29–6.64) | <0.001 | 3.28 (2.01–5.34) | <0.001 | 3.8 (2.69–5.38) | <0.001 | 4.53 (2.67–7.7) | <0.001 | 3.3 (2.02–5.38) | <0.001 |
| CD8 | ||||||||||||
| ≤500 | 1 | 1 | 1 | |||||||||
| >500 | 0.52 (0.39–0.69) | <0.001 | 0.41 (0.26–0.62) | <0.001 | 0.72 (0.49–1.07) | 0.104 | ||||||
| CD20 | ||||||||||||
| ≤400 | 1 | 1 | 1 | |||||||||
| >400 | 0.61 (0.4–0.94) | 0.025 | 0.73 (0.39–1.38) | 0.334 | 0.56 (0.3–1.03) | 0.061 | ||||||
| CD8 TNM, overall | CD8 TNM, LUSC | CD8 TNM, LUAD | ||||||||||
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |||||||
| Gender | ||||||||||||
| Female | 1 | 1 | 1 | |||||||||
| Male | 1.42 (1.05–1.92) | 0.024 | 1.72 (1.03–2.86) | 0.039 | 1.56 (1.05–2.33) | 0.027 | ||||||
| ECOG | ||||||||||||
| 0 | 1 | |||||||||||
| 1 | 1.42 (1.06–1.89) | 0.017 | ||||||||||
| 2 | 1.3 (0.7–2.42) | 0.412 | ||||||||||
| CD8 TNM, overall | CD8 TNM, LUSC | CD8 TNM, LUAD | ||||||||||
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |||||||
| Differentiation | ||||||||||||
| Poor | 1 | |||||||||||
| Moderate | 0.8 (0.59–1.07) | 0.135 | ||||||||||
| Well | 0.58 (0.36–0.95) | 0.029 | ||||||||||
| Vascular infiltration | ||||||||||||
| No | 1 | 1 | 1 | |||||||||
| Yes | 1.76 (1.26–2.47) | 0.001 | 2.2 (1.35–3.57) | 0.002 | 1.75 (1.07–2.84) | 0.024 | ||||||
| CD8 TNM | ||||||||||||
| Fav | 1 | 1 | 1 | |||||||||
| Int-Fav | 1.94 (1.19–3.16) | 0.007 | 2.45 (1.14–5.25) | 0.022 | 1.7 (0.9–3.21) | 0.102 | ||||||
| Int-Poor | 3 (1.87–4.83) | <0.001 | 3.4 (1.61–7.19) | 0.001 | 3.25 (1.74–6.05) | <0.001 | ||||||
| Poor | 7.41 (4.52–12.16) | <0.001 | 14.64 (6.89–31.14) | <0.001 | 4.67 (2.39–9.12) | <0.001 | ||||||
P-values below 0.05 are highlighted in bold. CD, cluster of differentiation; ECOG, eastern cooperative oncology group.